Bruker (BRKR) Net Income towards Common Stockholders (2010 - 2026)
Bruker's (BRKR) quarterly Net Income towards Common Stockholders came in at -$62.9 million in Q2 2026, down 927.63% on a YoY basis from $7.6 million in Q2 2025, and down 1897.14% quarter-over-quarter from $3.5 million in Q1 2026.
Analysis
Bruker (BRKR) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Bruker (BRKR) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$62.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 927.63% year-over-year to -$62.9 million; the trailing twelve-month figure through Jun 2026 stood at -$106.9 million (down 234.3% YoY), and the FY2025 full-year result was -$22.5 million, down 119.89% from the prior year.
- Net Income towards Common Stockholders slipped to -$62.9 million in Q2 2026 per BRKR's latest filing, from $3.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $205.5 million in Q4 2023 and bottomed at -$62.9 million in Q2 2026.
- Historically, Net Income towards Common Stockholders has averaged $41.9 million across 5 years, with a median of $45.2 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders surged 110.99% in 2023, then plunged 927.63% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at $97.4 million in 2022, then soared by 110.99% to $205.5 million in 2023, then slumped by 93.33% to $13.7 million in 2024, then rose by 8.76% to $14.9 million in 2025, then plunged by 522.15% to -$62.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$62.9 million, $3.5 million, and $14.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.48 Bn | 221.41 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 144.42 Bn | 140.08 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Agilent Technologies | 40.86 Bn | 39.11 Bn | 1.04 Bn | 362.00 Mn |
| 4 | Illumina | 30.97 Bn | 29.80 Bn | 770.00 Mn | 207.00 Mn |
| 5 | Revvity | 13.85 Bn | 12.83 Bn | 416.87 Mn | 51.82 Mn |
| 6 | Bio-Techne | 11.27 Bn | 11.01 Bn | 211.39 Mn | 54.62 Mn |
| 7 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | 371.40 Mn |
| 8 | Repligen | 9.33 Bn | 8.31 Bn | 110.04 Mn | 5.01 Mn |
| 9 | 10x Genomics | 8.77 Bn | 8.21 Bn | 112.50 Mn | -17.93 Mn |
| 10 | Bruker | 8.30 Bn | 8.09 Bn | 416.00 Mn | -62.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -62.90 Mn |
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 14.90 Mn |
| Sep 30, 2025 | -62.40 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 17.40 Mn |
| Dec 31, 2024 | 13.70 Mn |
| Sep 30, 2024 | 40.90 Mn |
| Jun 30, 2024 | 7.60 Mn |
| Mar 31, 2024 | 50.90 Mn |
| Dec 31, 2023 | 205.50 Mn |
| Sep 30, 2023 | 88.10 Mn |
| Jun 30, 2023 | 57.10 Mn |
| Mar 31, 2023 | 76.50 Mn |
| Dec 31, 2022 | 97.40 Mn |
| Sep 30, 2022 | 88.10 Mn |
| Jun 30, 2022 | 49.50 Mn |
| Mar 31, 2022 | 61.60 Mn |
| Dec 31, 2021 | 75.70 Mn |
| Sep 30, 2021 | 87.10 Mn |